{"transactions":[{"id":4637245,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-10-07T21:02:25.000Z","date":"2026-10-05","kind":"sale","planned":false,"acquired":false,"shares":294,"price":1.99,"value":585.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 above reflects the weighted average price of 337 shares sold by a broker on October 5, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis."}],"balance_after":81715,"source":{"system":"sec-edgar","filing":"0000905148-26-004399","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841088/000090514826004399/form4.xml","form_type":"4"}},{"id":672,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":574,"kind":"person","name":"Levin Michaela","position":1,"cik":"0002151012","reported_name":"Levin Michaela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-02T20:30:31.000Z","date":"2026-08-31","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the option vest on September 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":130000,"derivative":{"exercise_price":2.09,"expiration_date":"2036-08-30","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0000905148-26-004065","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2151012/000090514826004065/form4.xml","form_type":"4"}},{"id":671,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":574,"kind":"person","name":"Levin Michaela","position":1,"cik":"0002151012","reported_name":"Levin Michaela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-09-02T20:30:31.000Z","date":"2026-08-31","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on September 1, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000905148-26-004065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2151012/000090514826004065/form4.xml","form_type":"4"}},{"id":673504,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-08-27T20:14:53.000Z","date":"2026-08-25","kind":"sale","planned":false,"acquired":false,"shares":14036,"price":2.2064,"value":30969.0304,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2230052,"source":{"system":"sec-edgar","filing":"0000905148-26-003968","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003968/form4.xml","form_type":"4"}},{"id":680221,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:10:19.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":101,"price":2.01,"value":203.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":18033,"source":{"system":"sec-edgar","filing":"0000905148-26-003840","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514826003840/form4.xml","form_type":"4"}},{"id":679555,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:09:33.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":185,"price":2.01,"value":371.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":82009,"source":{"system":"sec-edgar","filing":"0000905148-26-003839","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003839/form4.xml","form_type":"4"}},{"id":679554,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:08:39.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":400,"price":2.01,"value":804.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":52592,"source":{"system":"sec-edgar","filing":"0000905148-26-003838","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003838/form4.xml","form_type":"4"}},{"id":679553,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:07:50.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":604,"price":2.01,"value":1214.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":146349,"source":{"system":"sec-edgar","filing":"0000905148-26-003837","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003837/form4.xml","form_type":"4"}},{"id":679552,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-08-20T20:07:06.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":484,"price":2.01,"value":972.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":385859,"source":{"system":"sec-edgar","filing":"0000905148-26-003836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003836/form4.xml","form_type":"4"}},{"id":679551,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-08-20T20:07:06.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":1229,"price":2.01,"value":2470.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2244088,"source":{"system":"sec-edgar","filing":"0000905148-26-003836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003836/form4.xml","form_type":"4"}},{"id":693846,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T20:34:32.000Z","date":"2026-08-04","kind":"sale","planned":false,"acquired":false,"shares":1142,"price":1.57,"value":1792.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":66008,"source":{"system":"sec-edgar","filing":"0000905148-26-003499","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003499/form4.xml","form_type":"4"}},{"id":703902,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-23T20:28:01.000Z","date":"2026-07-21","kind":"sale","planned":false,"acquired":false,"shares":573,"price":1.76,"value":1008.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":82194,"source":{"system":"sec-edgar","filing":"0000905148-26-003334","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003334/form4.xml","form_type":"4"}},{"id":730213,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:32:39.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to Dr. Derek DiRocco's continuous service through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0001231919-26-000686","document":"form4-06222026_080632.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000686/form4-06222026_080632.xml","form_type":"4"}},{"id":730070,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:14:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003042","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000090514826003042/form4.xml","form_type":"4"}},{"id":730038,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36224,"kind":"person","name":"Shacham Sharon","position":1,"cik":"0001588438","reported_name":"Shacham Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:13:12.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1588438/000090514826003041/form4.xml","form_type":"4"}},{"id":730760,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36407,"kind":"person","name":"Palani Santhosh","position":1,"cik":"0002013475","reported_name":"Palani Santhosh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:11:49.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003035","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013475/000090514826003035/form4.xml","form_type":"4"}},{"id":730363,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36299,"kind":"person","name":"Magovcevic-Liebisch Ivana","position":1,"cik":"0001279281","reported_name":"Magovcevic-Liebisch Ivana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:10:22.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279281/000090514826003034/form4.xml","form_type":"4"}},{"id":729977,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:09:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003033/form4.xml","form_type":"4"}},{"id":730055,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36227,"kind":"person","name":"BAUM CHARLES M","position":1,"cik":"0001579824","reported_name":"BAUM CHARLES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:08:11.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003024","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579824/000090514826003024/form4.xml","form_type":"4"}},{"id":763180,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-26T20:09:28.000Z","date":"2026-05-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":13729,"price":1.79,"value":24574.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2245317,"source":{"system":"sec-edgar","filing":"0000905148-26-002652","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002652/form4.xml","form_type":"4"}},{"id":769712,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:59:55.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of a restricted stock unit (\"RSU\") award to Derek DiRocco. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on March 18, 2027, subject to Dr. DiRocco's continuous service as a director through such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSUs and underlying common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0001231919-26-000517","document":"form4-05202026_080548.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000517/form4-05202026_080548.xml","form_type":"4"}},{"id":769613,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:36:35.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002563","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000090514826002563/form4.xml","form_type":"4"}},{"id":769596,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36224,"kind":"person","name":"Shacham Sharon","position":1,"cik":"0001588438","reported_name":"Shacham Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:36:13.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002562","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1588438/000090514826002562/form4.xml","form_type":"4"}},{"id":770244,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36407,"kind":"person","name":"Palani Santhosh","position":1,"cik":"0002013475","reported_name":"Palani Santhosh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:35:52.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002560","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013475/000090514826002560/form4.xml","form_type":"4"}},{"id":769795,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36299,"kind":"person","name":"Magovcevic-Liebisch Ivana","position":1,"cik":"0001279281","reported_name":"Magovcevic-Liebisch Ivana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:35:31.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002559","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279281/000090514826002559/form4.xml","form_type":"4"}},{"id":769403,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:33:47.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the RSUs for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs and underlying common stock."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002558","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002558/form4.xml","form_type":"4"}},{"id":769607,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36227,"kind":"person","name":"BAUM CHARLES M","position":1,"cik":"0001579824","reported_name":"BAUM CHARLES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:33:03.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002557","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579824/000090514826002557/form4.xml","form_type":"4"}},{"id":770252,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:31:42.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":14227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":18134,"source":{"system":"sec-edgar","filing":"0000905148-26-002556","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514826002556/form4.xml","form_type":"4"}},{"id":769599,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":30495,"kind":"person","name":"Mirza Mansoor Raza","position":1,"cik":"0001588389","reported_name":"Mirza Mansoor Raza","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:58.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":38817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":38817,"source":{"system":"sec-edgar","filing":"0000905148-26-002555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1588389/000090514826002555/form4.xml","form_type":"4"}},{"id":769401,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:36.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":49830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":82767,"source":{"system":"sec-edgar","filing":"0000905148-26-002553","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002553/form4.xml","form_type":"4"}},{"id":769399,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:16.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":46167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":67150,"source":{"system":"sec-edgar","filing":"0000905148-26-002552","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002552/form4.xml","form_type":"4"}},{"id":769400,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:29:50.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":38584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":52992,"source":{"system":"sec-edgar","filing":"0000905148-26-002551","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002551/form4.xml","form_type":"4"}},{"id":769398,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:29:31.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":72981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":146953,"source":{"system":"sec-edgar","filing":"0000905148-26-002550","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002550/form4.xml","form_type":"4"}},{"id":769397,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-20T20:29:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":72706,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":386343,"source":{"system":"sec-edgar","filing":"0000905148-26-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002549/form4.xml","form_type":"4"}},{"id":769396,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-20T20:29:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":180095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2259046,"source":{"system":"sec-edgar","filing":"0000905148-26-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002549/form4.xml","form_type":"4"}},{"id":775393,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:11:48.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":1.92,"value":190.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":3907,"source":{"system":"sec-edgar","filing":"0000905148-26-002502","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514826002502/form4.xml","form_type":"4"}},{"id":774268,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:11:25.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":184,"price":1.92,"value":353.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":32937,"source":{"system":"sec-edgar","filing":"0000905148-26-002501","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002501/form4.xml","form_type":"4"}},{"id":774266,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:11:02.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":404,"price":1.92,"value":775.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":14408,"source":{"system":"sec-edgar","filing":"0000905148-26-002500","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002500/form4.xml","form_type":"4"}},{"id":774265,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:10:39.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":1.92,"value":1176.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":73972,"source":{"system":"sec-edgar","filing":"0000905148-26-002499","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002499/form4.xml","form_type":"4"}},{"id":774264,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-18T20:10:14.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":490,"price":1.92,"value":940.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":313637,"source":{"system":"sec-edgar","filing":"0000905148-26-002498","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002498/form4.xml","form_type":"4"}},{"id":774263,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-05-18T20:10:14.000Z","date":"2026-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1253,"price":1.92,"value":2405.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2078951,"source":{"system":"sec-edgar","filing":"0000905148-26-002498","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002498/form4.xml","form_type":"4"}},{"id":801743,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T20:28:10.000Z","date":"2026-04-22","kind":"grant","planned":false,"acquired":true,"shares":3888888,"price":1.8,"value":6999998.4,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":11803094,"source":{"system":"sec-edgar","filing":"0001231919-26-000396","document":"form4-04232026_080403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000123191926000396/form4-04232026_080403.xml","form_type":"4"}},{"id":803494,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-21T21:05:48.000Z","date":"2026-04-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":558,"price":1.78,"value":993.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":33121,"source":{"system":"sec-edgar","filing":"0000905148-26-001768","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001768/form4.xml","form_type":"4"}},{"id":868730,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:22:28.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":31900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":31900,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":31900},"source":{"system":"sec-edgar","filing":"0000905148-26-001121","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514826001121/form4.xml","form_type":"4"}},{"id":865288,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":30495,"kind":"person","name":"Mirza Mansoor Raza","position":1,"cik":"0001588389","reported_name":"Mirza Mansoor Raza","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:21:24.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":174068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":174068,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":174068},"source":{"system":"sec-edgar","filing":"0000905148-26-001120","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1588389/000090514826001120/form4.xml","form_type":"4"}},{"id":864768,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:19:56.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":129760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":129760,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":129760},"source":{"system":"sec-edgar","filing":"0000905148-26-001119","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001119/form4.xml","form_type":"4"}},{"id":864767,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:19:00.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":132925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":132925,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":132925},"source":{"system":"sec-edgar","filing":"0000905148-26-001118","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001118/form4.xml","form_type":"4"}},{"id":864766,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:17:45.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":94946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":94946,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":94946},"source":{"system":"sec-edgar","filing":"0000905148-26-001117","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001117/form4.xml","form_type":"4"}},{"id":864765,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:16:29.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":186728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":186728,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":186728},"source":{"system":"sec-edgar","filing":"0000905148-26-001116","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001116/form4.xml","form_type":"4"}},{"id":864764,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:15:29.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":185495,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":185495,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":185495},"source":{"system":"sec-edgar","filing":"0000905148-26-001115","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001115/form4.xml","form_type":"4"}},{"id":864763,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:15:29.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":417210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":417210,"derivative":{"exercise_price":1.51,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":417210},"source":{"system":"sec-edgar","filing":"0000905148-26-001115","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001115/form4.xml","form_type":"4"}},{"id":883795,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-02-24T21:12:46.000Z","date":"2026-02-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":14265,"price":1.53,"value":21825.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2080204,"source":{"system":"sec-edgar","filing":"0000905148-26-001010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826001010/form4.xml","form_type":"4"}},{"id":897438,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:14:35.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":116,"price":1.63,"value":189.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":4006,"source":{"system":"sec-edgar","filing":"0000905148-26-000939","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514826000939/form4.xml","form_type":"4"}},{"id":895594,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:12:42.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":217,"price":1.63,"value":353.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":33679,"source":{"system":"sec-edgar","filing":"0000905148-26-000937","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000937/form4.xml","form_type":"4"}},{"id":895593,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:11:58.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":471,"price":1.63,"value":767.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":14812,"source":{"system":"sec-edgar","filing":"0000905148-26-000936","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000936/form4.xml","form_type":"4"}},{"id":895590,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:10:45.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":723,"price":1.63,"value":1178.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":74585,"source":{"system":"sec-edgar","filing":"0000905148-26-000935","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000935/form4.xml","form_type":"4"}},{"id":895592,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-02-18T21:09:33.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":579,"price":1.63,"value":943.77,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen?s spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":314127,"source":{"system":"sec-edgar","filing":"0000905148-26-000934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000934/form4.xml","form_type":"4"}},{"id":895591,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-02-18T21:09:33.000Z","date":"2026-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1302,"price":1.63,"value":2122.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson?s spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2094469,"source":{"system":"sec-edgar","filing":"0000905148-26-000934","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000934/form4.xml","form_type":"4"}},{"id":933989,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-21T21:02:10.000Z","date":"2026-01-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":659,"price":1.98,"value":1304.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":33896,"source":{"system":"sec-edgar","filing":"0000905148-26-000281","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000281/form4.xml","form_type":"4"}},{"id":936696,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2026-01-16T21:02:48.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":49000,"price":1.676,"value":82124.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.66 to $1.68, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2095771,"source":{"system":"sec-edgar","filing":"0000905148-26-000226","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000226/form4.xml","form_type":"4"}},{"id":936695,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-16T21:01:38.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":8832,"price":1.6983,"value":14999.3856,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4."}],"balance_after":20983,"source":{"system":"sec-edgar","filing":"0000905148-26-000225","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000225/form4.xml","form_type":"4"}},{"id":938272,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-15T21:38:05.000Z","date":"2026-01-13","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.7218,"value":17218.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.719 to $1.7268, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4."}],"balance_after":75308,"source":{"system":"sec-edgar","filing":"0000905148-26-000212","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826000212/form4.xml","form_type":"4"}},{"id":988313,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-11-25T21:03:56.000Z","date":"2025-11-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19904,"price":2.3,"value":45779.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2046771,"source":{"system":"sec-edgar","filing":"0000905148-25-004179","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004179/form4.xml","form_type":"4"}},{"id":996128,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:33:56.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":2.24,"value":221.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":4122,"source":{"system":"sec-edgar","filing":"0000905148-25-004131","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514825004131/form4.xml","form_type":"4"}},{"id":994999,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:32:18.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":184,"price":2.24,"value":412.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":34555,"source":{"system":"sec-edgar","filing":"0000905148-25-004130","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004130/form4.xml","form_type":"4"}},{"id":994997,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:35.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":403,"price":2.24,"value":902.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":15283,"source":{"system":"sec-edgar","filing":"0000905148-25-004129","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004129/form4.xml","form_type":"4"}},{"id":994996,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:29:50.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":2.24,"value":1373.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":65308,"source":{"system":"sec-edgar","filing":"0000905148-25-004128","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004128/form4.xml","form_type":"4"}},{"id":994995,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-11-18T21:28:44.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":490,"price":2.24,"value":1097.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":314706,"source":{"system":"sec-edgar","filing":"0000905148-25-004127","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004127/form4.xml","form_type":"4"}},{"id":994994,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-11-18T21:28:44.000Z","date":"2025-11-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59765,"price":2.24,"value":133873.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2066675,"source":{"system":"sec-edgar","filing":"0000905148-25-004127","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825004127/form4.xml","form_type":"4"}},{"id":1015108,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-21T20:06:48.000Z","date":"2025-10-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":558,"price":1.81,"value":1009.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":34739,"source":{"system":"sec-edgar","filing":"0000905148-25-003637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003637/form4.xml","form_type":"4"}},{"id":1024069,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":30495,"kind":"person","name":"Mirza Mansoor Raza","position":1,"cik":"0001588389","reported_name":"Mirza Mansoor Raza","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T20:28:11.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest on November 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":225000,"derivative":{"exercise_price":1.81,"expiration_date":"2035-09-30","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000905148-25-003507","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1588389/000090514825003507/form4.xml","form_type":"4"}},{"id":1023950,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-03T20:26:35.000Z","date":"2025-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":284,"price":1.81,"value":514.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":35297,"source":{"system":"sec-edgar","filing":"0000905148-25-003506","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003506/form4.xml","form_type":"4"}},{"id":1056543,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-08-25T20:39:41.000Z","date":"2025-08-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19905,"price":1.32,"value":26274.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2126440,"source":{"system":"sec-edgar","filing":"0000905148-25-003121","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003121/form4.xml","form_type":"4"}},{"id":1064211,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-08-18T21:19:21.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":1.39,"value":137.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":4221,"source":{"system":"sec-edgar","filing":"0000905148-25-003043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514825003043/form4.xml","form_type":"4"}},{"id":1063472,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-08-18T21:18:16.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":184,"price":1.39,"value":255.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":35581,"source":{"system":"sec-edgar","filing":"0000905148-25-003042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003042/form4.xml","form_type":"4"}},{"id":1063470,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-08-18T21:16:45.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":403,"price":1.39,"value":560.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":15686,"source":{"system":"sec-edgar","filing":"0000905148-25-003041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003041/form4.xml","form_type":"4"}},{"id":1063469,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-18T21:15:52.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":1.39,"value":852.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":65921,"source":{"system":"sec-edgar","filing":"0000905148-25-003040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003040/form4.xml","form_type":"4"}},{"id":1063468,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-08-18T21:14:25.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":490,"price":1.39,"value":681.1,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":315196,"source":{"system":"sec-edgar","filing":"0000905148-25-003039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003039/form4.xml","form_type":"4"}},{"id":1063467,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-08-18T21:14:25.000Z","date":"2025-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59766,"price":1.39,"value":83074.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2146345,"source":{"system":"sec-edgar","filing":"0000905148-25-003039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825003039/form4.xml","form_type":"4"}},{"id":1073857,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":25722,"kind":"person","name":"Levy Adam D.","position":1,"cik":"0002061876","reported_name":"Levy Adam D.","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-05T20:59:20.000Z","date":"2025-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1164,"price":1.26,"value":1466.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":12151,"source":{"system":"sec-edgar","filing":"0000905148-25-002732","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825002732/form4.xml","form_type":"4"}},{"id":1083801,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-07-21T20:28:26.000Z","date":"2025-07-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":558,"price":1.32,"value":736.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":35765,"source":{"system":"sec-edgar","filing":"0000905148-25-002493","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825002493/form4.xml","form_type":"4"}},{"id":1107641,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T00:17:31.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to Dr. Derek DiRocco's continuous service through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0001415889-25-017627","document":"form4-06182025_120627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1315082/000141588925017627/form4-06182025_120627.xml","form_type":"4"}},{"id":1107237,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T22:04:32.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002177","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825002177/form4.xml","form_type":"4"}},{"id":1107551,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36231,"kind":"person","name":"TOMSICEK MICHAEL JOHN","position":1,"cik":"0001570392","reported_name":"TOMSICEK MICHAEL JOHN","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T21:57:11.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002174","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1570392/000090514825002174/form4.xml","form_type":"4"}},{"id":1107531,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36224,"kind":"person","name":"Shacham Sharon","position":1,"cik":"0001588438","reported_name":"Shacham Sharon","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T21:54:43.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002173","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1588438/000090514825002173/form4.xml","form_type":"4"}},{"id":1108345,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36407,"kind":"person","name":"Palani Santhosh","position":1,"cik":"0002013475","reported_name":"Palani Santhosh","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T21:49:31.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002172","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013475/000090514825002172/form4.xml","form_type":"4"}},{"id":1107787,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36299,"kind":"person","name":"Magovcevic-Liebisch Ivana","position":1,"cik":"0001279281","reported_name":"Magovcevic-Liebisch Ivana","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T21:48:02.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002171","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1279281/000090514825002171/form4.xml","form_type":"4"}},{"id":1107544,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36227,"kind":"person","name":"BAUM CHARLES M","position":1,"cik":"0001579824","reported_name":"BAUM CHARLES M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T21:21:52.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002170","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579824/000090514825002170/form4.xml","form_type":"4"}},{"id":1134719,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-05-23T20:58:19.000Z","date":"2025-05-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":19904,"price":1.15,"value":22889.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2206111,"source":{"system":"sec-edgar","filing":"0000905148-25-001900","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001900/form4.xml","form_type":"4"}},{"id":1145769,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21301,"kind":"person","name":"Peterson Katharine","position":1,"cik":"0002022214","reported_name":"Peterson Katharine","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-05-16T20:21:13.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":99,"price":1.14,"value":112.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":4320,"source":{"system":"sec-edgar","filing":"0000905148-25-001824","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022214/000090514825001824/form4.xml","form_type":"4"}},{"id":1144661,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21132,"kind":"person","name":"Miller Mary","position":1,"cik":"0001841088","reported_name":"Miller Mary","relationship":{"officer":true,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-05-16T20:20:06.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":184,"price":1.14,"value":209.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":36323,"source":{"system":"sec-edgar","filing":"0000905148-25-001823","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001823/form4.xml","form_type":"4"}},{"id":1144660,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21131,"kind":"person","name":"Gamelin Erick","position":1,"cik":"0001950551","reported_name":"Gamelin Erick","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-05-16T20:18:26.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":403,"price":1.14,"value":459.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":16089,"source":{"system":"sec-edgar","filing":"0000905148-25-001822","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001822/form4.xml","form_type":"4"}},{"id":1144659,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":21130,"kind":"person","name":"Devroe Eric","position":1,"cik":"0001950573","reported_name":"Devroe Eric","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-16T20:17:04.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":613,"price":1.14,"value":698.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."}],"balance_after":66534,"source":{"system":"sec-edgar","filing":"0000905148-25-001821","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001821/form4.xml","form_type":"4"}},{"id":1144658,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-05-16T20:16:01.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":491,"price":1.14,"value":559.74,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":315686,"source":{"system":"sec-edgar","filing":"0000905148-25-001820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001820/form4.xml","form_type":"4"}},{"id":1144657,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":18970,"kind":"person","name":"Blume-Jensen Peter","position":1,"cik":"0001950499","reported_name":"Blume-Jensen Peter","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}},{"id":18971,"kind":"person","name":"Masson Kristina","position":2,"cik":"0001950501","reported_name":"Masson Kristina","relationship":{"director":true,"officer":true,"officer_title":"EVP - Business Operations"}}],"security":"Common Stock","published_at":"2025-05-16T20:16:01.000Z","date":"2025-05-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":59766,"price":1.14,"value":68133.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein."}],"balance_after":2226015,"source":{"system":"sec-edgar","filing":"0000905148-25-001820","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825001820/form4.xml","form_type":"4"}},{"id":1162672,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-01T23:07:20.000Z","date":"2025-05-01","kind":"sale","planned":false,"acquired":false,"shares":298886,"price":1.34,"value":400507.24,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.33 to $1.39 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3104139,"source":{"system":"sec-edgar","filing":"0001062993-25-008341","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299325008341/form4.xml","form_type":"4"}},{"id":1162671,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-01T23:07:20.000Z","date":"2025-04-30","kind":"sale","planned":false,"acquired":false,"shares":437881,"price":1.41,"value":617412.21,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.40 to $1.53 inclusive. The reporting persons undertake to provide Acrivon Therapeutics, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3403025,"source":{"system":"sec-edgar","filing":"0001062993-25-008341","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299325008341/form4.xml","form_type":"4"}},{"id":1164064,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-29T23:26:12.000Z","date":"2025-04-29","kind":"sale","planned":false,"acquired":false,"shares":250000,"price":1.41,"value":352500.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.40 to $1.49 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3840906,"source":{"system":"sec-edgar","filing":"0001062993-25-008214","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299325008214/form4.xml","form_type":"4"}},{"id":1164063,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-29T23:26:12.000Z","date":"2025-04-28","kind":"sale","planned":false,"acquired":false,"shares":215283,"price":1.56,"value":335841.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.54 to $1.65 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":4090906,"source":{"system":"sec-edgar","filing":"0001062993-25-008214","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299325008214/form4.xml","form_type":"4"}},{"id":1164062,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-29T23:26:12.000Z","date":"2025-04-25","kind":"sale","planned":false,"acquired":false,"shares":1054669,"price":1.95,"value":2056604.55,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.61 to $2.39 inclusive. The reporting persons undertake to provide Acrivon Therapeutics, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\"). Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":4306189,"source":{"system":"sec-edgar","filing":"0001062993-25-008214","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299325008214/form4.xml","form_type":"4"}}],"next_cursor":"2025-04-29T23:26:12.000000Z,1164062"}